ImmunityBio (IBRX) Total Current Liabilities (2014 - 2026)

ImmunityBio (IBRX) has 13 years of Total Current Liabilities data on file, last reported at $68.0 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 38.1% year-over-year to $68.0 million in Q1 2026; TTM through Mar 2026 was $68.0 million, a 38.1% increase from a year earlier, with the FY2025 full-year figure at $61.8 million, up 12.39% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $68.0 million, up from $61.8 million in the prior quarter.
• Over the last five years, Total Current Liabilities for IBRX reached as high as $613.5 million in Q2 2023 and fell as low as $49.2 million in Q1 2025.
• Historically, Total Current Liabilities has averaged $186.7 million across 5 years, with a median of $62.1 million in 2024.
• Across the five-year window, Total Current Liabilities surged 405.25% in 2022 and sank 90.48% in 2024, its largest moves.
• Year by year, Total Current Liabilities stood at $500.9 million in 2022, then slumped by 88.36% to $58.3 million in 2023, then declined by 5.73% to $54.9 million in 2024, then rose by 12.39% to $61.8 million in 2025, then gained by 10.04% to $68.0 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $68.0 million in Q1 2026, $61.8 million in Q4 2025, and $57.1 million in Q3 2025.